Navigation Links
GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
Date:4/24/2013

LONDON, April 24, 2013 /PRNewswire/ --

GlaxoSmithKline reported a 2% decline in Group revenues in line with expectations and a dividend increase of 6% as part of its 2013 Q1 results. The pharmaceutical giant also officially announced the divestment of Lucozade and Ribena as well as the creation of a 'Global Established Products' group within its portfolio that would get a different strategic focus from the more innovative products.

In a video interview, Chief Financial Officer Simon Dingemans said he felt "very comfortable" about the trends the group was seeing from its performance with strong results from Japan and the US offsetting the tougher European environment.

He emphasized his confidence that the Group was on track to deliver the guidance of 3 to 4% earnings growth in constant currency terms, on sales growth of around 1%. He also highlighted the "significant, continued progress" GSK was making in the pipeline with six new products that had been "called out in front of regulators on both sides of the Atlantic".

The video interview and transcript are available to watch now for free at http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
2. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
3. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
4. Texas A&M System and GlaxoSmithKline receive U.S. Government approval to establish influenza vaccine facility in Texas
5. Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
6. GlaxoSmithKline advances multi-city discussion focused on improving the health of US communities
7. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
8. GlaxoSmithKline honors healthcare nonprofits with $40,000 IMPACT Award
9. GlaxoSmithKline Sales Down in Q3 against Good Underlying Momentum in the Business
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. GlaxoSmithKlines (GSK) $3 Billion Whistleblower Settlement Has Paid for One Of Americas Most Expensive Failed Corporate Internal Investigations, Qui Tam Whistleblowers Attorneys Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... the EMR (Electronic Medical Records) market in a recent ... International sales, vendor switches, Increased physician usage, a growing market ... trends were noted in Kalorama,s report EMR ... The report marks Kalorama,s seventh complete study of the ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Horizon Blue ... been honored as one of the nation’s most accomplished business technology innovators by ... received the recognition for technology achievements that have enabled the delivery of the ...
(Date:5/3/2016)... ... 03, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the Wynn & ... conference for the specialty pharmacy industry, with thousands of pharmacy providers, pharma/biotech manufacturers, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... announced that it is launching a new client service center in La Vergne, ... Texas, and will provide the full range of Empyrean client services. , “Our ...
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter ... or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 ... Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the ...
(Date:5/3/2016)... ... May 03, 2016 , ... For ... top Information and Communication Technology (ICT) companies in the annual Branham300 listing. For ... operating in Canada, as ranked by revenue. , “We are honored to ...
Breaking Medicine News(10 mins):